Get started
Work

Supplementary Table S1 from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table S1 - PDF file Percent change from baseline in serum C-reactive protein concentration (mg/L) in Cohort 7
DOI: 10.1158/1078-0432.22451112
Authors: Razelle Kurzrock, Peter M. Voorhees, Corey Casper, Richard R. Furman, Luis Fayad, Sagar Lonial, Hossein Borghaei, Sundar Jagannath, Lubomir Sokol, Saad Z. Usmani, Helgi van de Velde, Xiang Qin, Thomas A. Puchalski, Brett Hall, Manjula Reddy, Ming Qi, Frits van Rhee
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361882973
Cites:
Cited by:
Related to: 10